CTNNB1 and acute myeloid leukemia: This is in contrast to previous studies that showed efficacy of BC2059 in multiple myeloma and acute myeloid leukemia, tumors that typically have a upregulated Wnt/β-catenin pathway, but are not mutated for the CTNNB1 gene [22, 30].